Jump to content

Property:Specifications on cancer therapies

From CAMIH

This is a property of type Text.

Showing 20 pages using this property.
R
CAPOX (capecitabine + oxaliplatin) schedule; capecitabine; 5-fluorouracil and folinic acid  +
External beam radiotherapy: LINAC or Cobalt-10, total mean radiation dose (SD): 62.3 (9.13), radiotherapy duration (wks) (SD): 7.38 (1.28); daily fractions of 180– 200 cGy lasting from 5 to 9 weeks, for a total dose of 45-70 Gy, the radiation fields were the same for all patients, and the tongue was always included  +
Mean times from the last chemotherapy, last surgery, or last radiotherapy were comparable between groups (all 𝑃 values >0.25)  +
Standard fractionated RT (~1.8–2.4 Gy per session) for four to seven weeks with or without boost for a total radiation dose of ≥ 42 Gy Prior (n(%)): * Lumpectomy 27 (90%) * Mastectomy 3 (10%) * Chemotherapy before radiation 13 (43.3%)  +
S
Mean value (range) Radiation dose Aloe arm: 65.54 (50-70) Gy Placebo arm : 66.15 (54 - 70) Gy Previous chemotherapy per arm: Aloe arm: yes = 9 (69.2%); no = 4 (30.8%) Placebo arm: yes = 12 (92.3%); no = 1 (7.7%) Histology: SCC: Aloe arm = 11 (84.6%); Placebo arm = 12 (92.3%) Mucoepidermoid carcinoma: Aloe arm = 1 (7.7%); Placebo arm = 0 Osteosarcoma: Aloe arm = 1 (7.7%); Placebo arm = 1 (7.7%)  +
Oxiplatin-based chemotherapy (oxaliplatin + 5‑fluorouracil + leucovorin (FOLFOX4); oxaliplatin: 85 mg/m 2 intravenous (IV) on day 1, 5‑fluorouracil: 400 mg/m 2 IV bolus, followed by 600 mg/m 2 IV continuous infusion for 22 h on days 1 and 2, leucovorin: 200 mg/m 2 IV on days 1 and 2 as a 2‑h infusion before 5‑fluorouracil)  +
In all patients: High (>90%) emetic risk * 5-Flouracil + epirubicin + cyclophosphamide (FEC): 45% (SD 75.0) * Docetaxel + doxorubicin and cyclophosphamide (TAC): 7% (SD 11.7) Low (10—30%) emetic risk * Docetaxel: 8% (SD 13.3)  +
Radiation therapy alone or as postoperative radiation therapy, all patients were treated with Cobalt-60 or 6 MV photon machine, daily fractionation was 1.8 to 2 Gy, a total dose of 50 to 70 Gy over 5 to 7 weeks was administered  +
All patients treated with Cobalt 60 or 6 MV photon treatment machines, the daily fractionation was 2 Gy in 5 weekly fractions  +
Intervention arm: 36 mg/m<sup>2</sup> docetaxel for 30-minute infusion on days 2, 9, and 16; and 8-mg oral dexamethasone about 12 hours, 3 hours, and 1 hour before docetaxel; nine doses of dexamethasone per 28-day, continued for up to 30 weeks or until unacceptable docetaxel toxicity or clinical disease progression Control arm: 1-hour infusion of docetaxel at 75 mg/m<sup>2</sup> body-surface area on day 2; and 8-mg oral dexamethasone about 12 hours, 3 hours, and 1 hour before docetaxel infusion; three doses per 21-day cycle, continued for up to 30 weeks or until unacceptable docetaxel toxicity or clinical disease progression  +